Ask HopeStage to review this study with me
Leave your email and HopeStage can help you better understand this study.
Study reference: NCT07096791. HopeStage can help you review the study, but cannot decide medical eligibility.
Not Yet RecruitingNCT07096791
KH607 Tablets for depression
This study is not yet recruiting in Global. It is testing KH607 Tablets for depression.
DepressionDrugFrom 18 Years to 45 Years
Key information made simple
This study is comparing KH607 tablet with placebo for people with Postpartum depression. Participants receive KH607 tablet or placebo and complete study visits and assessments. Some participants may receive placebo instead of the study treatment, and direct benefit is not guaranteed.
Your next step
The official record does not clearly spell out the visit format, but it appears to be coordinated directly by the research team. Participation appears to involve guided sessions or support activities with check-ins on how they fit into daily life. The main fit is usually matching the main diagnosis and being able to understand the study and consent, while common reasons not to take part include safety concerns that need urgent care first and other treatments that could interfere with the study. This is an early-stage study, which usually means a smaller group and a focus on learning how the approach behaves.
Questions to ask before joining
- What are the exact eligibility criteria, and what could exclude someone?
- How many visits, assessments, or follow-ups are expected, and over what period?
- What risks, side effects, practical burdens, or alternatives should be understood first?
- Who should be contacted to confirm locations, timing, compensation, and next steps?
Things to check before joining
- Sponsor
- Chengdu Kanghong Pharmaceutical Group Co., Ltd.
- Sponsor type
- Pharmaceutical company
- Main activity
- medication or study treatment
- Intervention
- Not available
- Time commitment
- multiple visits or assessments
- Study phase
- Not available
- Enrollment
- Not available
- Recruitment status
- Not Yet Recruiting
- Source
- Official registry link
Key study information
- Official title
- A Phase 2 Study to Evaluate Efficacy and Safety of KH607 Tablets in Woman With Postpartum Depression
- Condition
- Postpartum Depressive Disorder
- Study status
- Not Yet Recruiting
- Sponsor / lead affiliation
- Chengdu Kanghong Pharmaceutical Group Co., Ltd.
- Location / country
- Global
- Registry
- ClinicalTrials.gov
- External trial ID
- NCT07096791
Why this study may matter
This study may matter because it adds public evidence around depression. HopeStage presents it as a starting point for understanding the study, checking the official source, and preparing questions with a care team.
For you
Taking part may give access to a new approach being evaluated.
It requires regular follow-up, often through questionnaires or interviews.
Registry reference
This page links back to the public source record so people can verify details directly with the registry and research team.
If you want the full study description, eligibility criteria, locations, and sponsor information in the original format, this is the place to check before taking the next step.
- Official title
- A Phase 2 Study to Evaluate Efficacy and Safety of KH607 Tablets in Woman With Postpartum Depression
- Source
- ClinicalTrials.gov
- Official registry link
- Open official registry
- External trial ID
- NCT07096791
Not medical advice
Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com
Questions about this study
What is KH607 Tablets for depression?
This study is exploring medication or study treatment for people with depression. Participants may complete study visits, assessments, or follow-up activities defined by the research team. It includes a comparison with placebo. Direct benefit is not guaranteed.
Who is behind this study, and what type of sponsor is it?
This study is sponsored by Chengdu Kanghong Pharmaceutical Group Co., Ltd.. Based on the sponsor name or official registry information, it appears to be a pharmaceutical company. You should verify the details in the official registry record.
What does participation involve, what phase is it, and what should I ask about safety?
This study may involve medication or study treatment, study visits, and assessments. The time commitment is multiple visits or assessments. The study phase is not available in HopeStage data. Check the official source record to see whether a phase is listed. Enrollment is not available in HopeStage data. HopeStage cannot say whether a study is safe or right for you. Before joining, ask the research team about possible risks, time commitment, visits, side effects, compensation, safety monitoring, and whether participation may affect your current care.
Where can I verify the study details?
Use the official source record linked on this page to check the full study description, recruitment status, eligibility criteria, locations, sponsor information, phase, enrollment, contact details, and any listed risks or requirements.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit me